Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells

Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. However, limited studies have been conducted to study the effect of this drug on myeloid cell function. Hence, we studied the effect of ibrutinib treatment on TLR-4 mediated...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncoimmunology
Prif Awduron: Natarajan, Gayathri, Terrazas, Cesar, Oghumu, Steve, Varikuti, Sanjay, Dubovsky, Jason A, Byrd, John C, Satoskar, Abhay R
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2015
Pynciau:
Brief Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4760285/
https://ncbi.nlm.nih.gov/pubmed/26942065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1057385
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg